** Shares of Australian drugmaker Mayne Pharma MYX.AX fall as much as 7.7% to A$4.11, their lowest since Aug. 23
** Co provides no update on potential buyout interest, at its annual general meeting
** MYX earlier in the month said Jefferies to assist co in terms of looking for a possible bidder
** Stock posts its biggest intraday pct fall since Nov. 13
** Co says total revenue for the July-Oct period came in at A$132.5 mln ($86.32 mln), lower than the A$137 mln reported in the previous corresponding period
** Two analysts covering the stock rate it "buy" or higher, their median PT is A$2.0 – LSEG data
** Stock had fallen 32.7% this year, as of last close
($1 = 1.5349 Australian dollars)
(Reporting by Nichiket Sunil)
((Nichiket.Sunil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。